Artificial invaplex

Artificial invaplex

  • CN 101,711,165 B
  • Filed: 03/27/2007
  • Issued: 02/24/2016
  • Est. Priority Date: 03/27/2007
  • Status: Active Grant
First Claim
Patent Images

1. artificial invaplex, it is characterized in that the invasion albumen composition with the serotype specificity lipopolysaccharide component compound from gram negative bacteria, wherein said invasion albumen composition is made up of IpaB:

  • IpaC complex, wherein said invasion albumen composition obtains by IpaB and IpaC is mixed to form IpaB;

    IpaC complex, wherein said IpaC and IpaB exists with the ratio in the scope of 0.08;

    1 to 80;

    1, and described artificial invaplex is by mixing by described IpaB;

    IpaC complex with serotype specificity lipopolysaccharide (LPS) component of at least one from gram negative bacteria and obtain, wherein said LPS exists with the ratio be selected from the scope of 0.01;

    1 to 10;

    1 relative to described IpaB;

    IpaC complex, wherein said serotype specificity lipopolysaccharide group is divided to come from and is selected from shigella flexneri (S.flexneri), bacillus ceylonensis A (S.sonnei), the Shigella of shigella dysenteriae (S.dysenteriae) or Shigella bogdii (S.boydii).

View all claims

    Thank you for your feedback